Evidence map›Paper›PMID 34931005›Full record

ArticleCommunications biology2021

Chemokines modulate glycan binding and the immunoregulatory activity of galectins.

Lucía Sanjurjo, Iris A Schulkens, Pauline Touarin, Roy Heusschen, Ed Aanhane, Kitty C M Castricum, Tanja D De Gruijl, Ulf J Nilsson, Hakon Leffler, Arjan W Griffioen and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Communications biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 3 countries.

Lucía SanjurjoAmsterdam UMC location VUmc, Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam, The Netherlands.ORCID http://orcid.org/0000-0003-4006-8010
Iris A SchulkensAmsterdam UMC location VUmc, Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam, The Netherlands.
Pauline TouarinLaboratoire d'Ingénierie des Systèmes Macromoléculaires (LISM), Institut de Microbiologie de la Méditerranée (IMM), CNRS - Aix-Marseille Université, UMR7255, Marseille, France.
Roy HeusschenAmsterdam UMC location VUmc, Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam, The Netherlands.
Ed AanhaneAmsterdam UMC location VUmc, Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam, The Netherlands.
Kitty C M CastricumAmsterdam UMC location VUmc, Department of Radiation Oncology, Cancer Center Amsterdam, Amsterdam, The Netherlands.
Tanja D De GruijlAmsterdam UMC location VUmc, Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam, The Netherlands.
Ulf J NilssonLund University, Department of Chemistry, Centre for Analysis and Synthesis, Lund, Sweden.ORCID http://orcid.org/0000-0001-5815-9522
Hakon LefflerLund University, Department of Laboratory Medicine, Section MIG, Lund, Sweden.ORCID http://orcid.org/0000-0003-4482-8945
Arjan W GriffioenAmsterdam UMC location VUmc, Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam, The Netherlands.
Latifa ElantakLaboratoire d'Ingénierie des Systèmes Macromoléculaires (LISM), Institut de Microbiologie de la Méditerranée (IMM), CNRS - Aix-Marseille Université, UMR7255, Marseille, France.
Rory R KoenenMaastricht University, Department of Biochemistry, Cardiovascular Research Institute Maastricht (CARIM), Maastricht, The Netherlands.
Victor L J L ThijssenAmsterdam UMC location VUmc, Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam, The Netherlands. v.thijssen@amsterdamumc.nl.ORCID http://orcid.org/0000-0002-6146-1842
Amsterdam University Medical Centers · NLCentre National de la Recherche Scientifique · FRLund University · SEMaastricht University · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Galectins are versatile glycan-binding proteins involved in immunomodulation. Evidence suggests that galectins can control the immunoregulatory function of cytokines and chemokines through direct binding. Here, we report on an inverse mechanism in which chemokines control the immunomodulatory functions of galectins. We show the existence of several specific galectin-chemokine binding pairs, including galectin-1/CXCL4. NMR analyses show that CXCL4 binding induces changes in the galectin-1 carbohydrate binding site. Consequently, CXCL4 alters the glycan-binding affinity and specificity of galectin-1. Regarding immunomodulation, CXCL4 significantly increases the apoptotic activity of galectin-1 on activated CD8

Indexed as

ImmunomodulationChemokine CXCL5Galectin 1GalectinsHumansJurkat CellsPlatelet Factor 4PolysaccharidesChemokine CXCL5CXCL5 protein, humanGalectin 1GalectinsLGALS9 protein, humanPF4 protein, humanPlatelet Factor 4Polysaccharides

Identifiers

PMID34931005
PMCPMC8688422
OpenAlexW4200424666

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.